Turmeric Efficacy for Mobility and Joint Function
Turmeric Efficacy for Mobility and Joint Function
The objective of the study is to test the capacity of a 12-weeks Turmipure GOLD®
 supplementation to reduce joint discomfort.
The aim of this clinical study is to determine whether oral administration of Turmipure GOLD®
 can contribute to the improvement of mobility and joint function in adult population with
 knee discomfort and with distinct Kellgren-Lawrence (K&L) knee radiographic scores.
Inclusion Criteria:

 -  Consent to the study and to comply with study product

 -  Who have a BMI between 18 and 32 kg/m²

 -  Who has mild to moderate knee pain for at least 3 months before enrollment (VAS
 between 40 to 70 on 100mm scale after respecting a washout period depending on the
 half-life of the excluded medications)

 -  Who has radiographic evidence of Kellgren-Lawrence score 0, 1, 2 and 3 in the
 tibio-femoral compartment of the target knee

 -  Who is able to perform the physical performance-based tests and understands all
 questions from the WOMAC questionnaire

 -  Who is willing to refrain from taking any pain reliever (OTC or prescription) and
 other pharmacological, nutritional agent (e.g. glucosamine), device or therapy (e.g.
 acupuncture) which may influence the study outcome during the entire trial (other than
 determined authorized rescue medication)

 -  Who is willing to not change dietary habits, level of physical activity (including any
 heavy physical work with high loading of the knee joints) and body weight

 Exclusion Criteria:

 -  Subjects with any clinically significant levels of the safety parameters at screening

 -  Pregnant or lactating females, or wishing to become pregnant during the study

 -  Subject with joint pain related to some predisposing conditions that have adversely
 altered the joint tissues often due to a specific cause

 -  Subject with Kellgren-Lawrence grade 4 in the tibio-femoral compartment of the target
 knee

 -  Who has clinically apparent tense effusion of the target knee or other joint

 -  Who has/had viscosupplementation in any joint including the target knee or other joint
 within 6 months prior to screening

 -  Who has concomitant inflammatory disease or other condition that affects the joints
 deemed exclusionary by the Principal Investigator (e.g. rheumatoid arthritis,
 metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active
 infection, etc…)

 -  Who has symptomatic osteoarthritis of the contralateral knee that is not responsive to
 paracetamol and requires other therapy

 -  Who is taking any treatment/supplementation which may interfere with study conduct and
 interpretation of study results (4-weeks washout, e.g. glucosamine, chondroitin,
 corticosteroids) except calcium and vitamin D supplements

 -  Who is under any medical condition deemed exclusionary by the Principal Investigator

 -  Subject has a history of drug and / or alcohol abuse at the time of enrollment

 -  Change of dietary habit within the preceding month

 -  Subject with known organic disease, including an inflammatory bowel disease, a benign
 or malign tumor of intestine or colon and significant systemic disease

 -  Subject currently involved in any other clinical trial or having participated in a
 trial within the preceding 90 days

 -  Subject with known allergy to components of the test product

 -  Subject has any concurrent medical or psychiatric condition that, in the opinion of
 the Investigator, would compromise his/her ability to comply with the study
 requirements

 -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous
 skin carcinoma, prostate cancer or carcinoma in situ with no significant progression
 over the past 2 years

 -  Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune
 disorder, or metabolic/endocrine disorders or other disease that would preclude
 supplement ingestion and/or assessment of safety and the study objectives

 -  Current illnesses which could interfere with the study (e.g. prolonged severe
 diarrhea, regurgitation/severe, difficulty swallowing)

 -  Who is taking any anticoagulant or heparin treatment